Bioventus Inc.
BVS Healthcare Medical Devices
Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 3.76%, EPS grew 345.5%, free cash flow fell 25.1% and total debt fell 27.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow BVS
Bioventus Inc. (BVS) EV/Sales
As of 16 October 2026, Bioventus Inc. (BVS) trades at a EV/Sales of 1.9×. Over the past ten years it has ranged from 0.5× (March 2021) to 2.6× (June 2021); the current reading is higher than 80% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.3× | (23.32%) |
| FY2024 | 1.7× | 26.45% |
| FY2023 | 1.3× | 25.25% |
| FY2022 | 1.1× | (52.33%) |
| FY2021 | 2.2× | 268.46% |
| FY2020 | 0.6× | 0.00% |
| FY2019 | 0.6× | 0.00% |
| FY2018 | 0.6× | 0.00% |
| FY2017 | 0.6× | 0.00% |
| FY2016 | 0.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | 0.10% |
| Mar 2026 | 1.5× | 13.56% |
| Dec 2025 | 1.3× | 0.65% |
| Sep 2025 | 1.3× | (2.68%) |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LMRI Lumexa Imaging Holdings, Inc. compare | 1.0× |
| ENOV Enovis Corporation compare | 1.0× |
| TNDM Tandem Diabetes Care, Inc. compare | 1.2× |
| IART Integra LifeSciences Holdings Corporation compare | 1.6× |
| BVS Bioventus Inc. | 1.9× |
| PRCT PROCEPT BioRobotics Corporation compare | 2.5× |
| AORT Artivion, Inc. compare | 2.9× |
| CBLL CeriBell, Inc. compare | 8.3× |
| IRMD iRadimed Corporation compare | 12.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)